One of the officially approved medications for the treatment of the pandemic disease COVID-19, caused by the SARS-CoV-2 virus, is remdesivir. This antiviral mole-cule is a prodrug that is metabolized into its active form (an ATP analogue). Because of its hepatotoxicity and ne-phrotoxicity, it is necessary to monitor the serum concen-trations of remdesivir. For the therapeutic drug monitoring of remdesivir, a method using liquid chromatography with tandem mass spectrometry (LC-MS/MS) in positive elec-trospray ionization mode was developed. Mass detection was done via triple quadrupole in the Multiple reaction monitoring mode. Separation was done on Zorbax C18 column at 35 °C in mobile phase gradient and flow 0.4mLmin–1(A –0.1% formic acid in water, B –0.1% formic acid in 95% acetonitrile). Time of analysis was 4minutes. LC-MS/MS method was successfully validated. Calibration was done in blood serum and plasma and it was linear in the range of tested concentrations (0–1000 ngmL–1). Samples were prepared by protein precipitation. The method was used to measure remdesivir concentration in a patient with SARS-CoV-2 infection. The measured concentration 60 minutes after remdesivir application was 175±15 ngmL–1.
- Klíčová slova
- remdesivir,
- MeSH
- antivirové látky * analýza farmakokinetika krev MeSH
- chromatografie kapalinová metody MeSH
- lidé MeSH
- monitorování léčiv metody přístrojové vybavení MeSH
- SARS-CoV-2 účinky léků MeSH
- tandemová hmotnostní spektrometrie metody MeSH
- výzkumný projekt MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
